Point72 Asset Management
VERA icon

Point72 Asset Management’s Vera Therapeutics VERA Stock Holding History

Point72 Asset Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$358K Buy
+8,900
New +$383K ﹤0.01% 3291

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management's VERA Position: Q1 2026 in Review

Point72 Asset Management reduced its Vera Therapeutics (VERA) stake by 30% in Q1 2026, selling an estimated $22.7M and leaving 1,210,725 shares worth $48.7M. The position accounts for 0.06% of the portfolio, ranked #381.

Point72 Asset Management first reported a position in VERA in Q3 2022 and has held it in 10 quarters since. The position peaked at $88M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Point72 Asset Management held 1,210,725 shares of Vera Therapeutics worth $48.7M as of Q1 2026.
  • Point72 Asset Management sold 527,660 Vera Therapeutics shares in Q1 2026, an estimated $22.7M.
  • Vera Therapeutics made up 0.06% of Point72 Asset Management's portfolio in Q1 2026, its #381 holding.
  • Point72 Asset Management first reported a position in Vera Therapeutics in Q3 2022 and has held it in 10 quarters since.
  • Point72 Asset Management's Vera Therapeutics position peaked at $88M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.